Soligenix Inc. (SNGX.OB) Announces Publication Concerning Stability of Lead Vaccine, RiVax
Soligenix Inc is a late-stage biotechnology company developing products to treat the life-threatening side effects of cancer treatments and gastrointestinal diseases, as well as vaccines for certain bioterrorism agents. RiVax™ is the company’s proprietary vaccine developed to protect against exposure to ricin toxin, a plant toxin with the potential to be a bioterror threat. RiVax is the most advanced vaccine in the company's portfolio. The company today issued a press release pointing to the February 2010 edition of Vaccine, in which an article describing prelinical formulations of RiVax was published. RiVax is currently being evaluated in phase 1 human safety…